Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Company news > 2019 > i2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactions

i2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactions

Read also

Gossamer Bio
Gossamer Bio
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Amgen opens new drug substance
Amgen opens new drug substance
Amgen opens new drug substance facility in North Carolina, US
BIA report
BIA report
BIA report: UK biotech investment surged to £3.5bn in 2024
MSD wins FDA
MSD wins FDA
MSD wins FDA priority review for Welireg in rare endocrine cancer
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand